ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX | N214846 | SUMITOMO PHARMA AMERICA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Sumitomo Pharma Switzerland GmbH et al v. Annora Pharma Private Limited et al 4 patentsANDA 220123relugolix, estradiol, norethindrone acetate | D. Del. | 2025-03-27 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$45.26
per ea
Lowest NADAC/Unit
$45.26
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 72974041501MYFEMBREE 40 MG-1 MG-0.5 MG TB | $45.26 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Code | Date | Status |
|---|---|---|
| M-289 | Jan 27, 2026 | Expired |